On Tuesday, NewAmsterdam Pharma Company NV (NASDAQ: NAMS) was -6.13% drop from the session before settling in for the closing price of $20.24. A 52-week range for NAMS has been $14.06 – $27.29.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 34.27% over the past five years. When this article was written, the company’s average yearly earnings per share was at 30.33%. With a float of $62.35 million, this company’s outstanding shares have now reached $108.06 million.
Let’s look at the performance matrix of the company that is accounted for 68 employees. In terms of profitability, gross margin is 99.85%, operating margin of -370.98%, and the pretax margin is -512.33%.
NewAmsterdam Pharma Company NV (NAMS) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward NewAmsterdam Pharma Company NV stocks. The insider ownership of NewAmsterdam Pharma Company NV is 44.41%, while institutional ownership is 47.10%. The most recent insider transaction that took place on Apr 11 ’25, was worth 21,669,878. Before that another transaction happened on Mar 26 ’25, when Company’s Director bought 1,135 for $22.49, making the entire transaction worth $25,521. This insider now owns 3,013,569 shares in total.
NewAmsterdam Pharma Company NV (NAMS) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 30.33% per share during the next fiscal year.
NewAmsterdam Pharma Company NV (NASDAQ: NAMS) Trading Performance Indicators
You can see what NewAmsterdam Pharma Company NV (NAMS) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 8.08. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 46.78.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.60, a number that is poised to hit -0.50 in the next quarter and is forecasted to reach -1.84 in one year’s time.
Technical Analysis of NewAmsterdam Pharma Company NV (NAMS)
NewAmsterdam Pharma Company NV (NASDAQ: NAMS) saw its 5-day average volume 0.8 million, a negative change from its year-to-date volume of 0.9 million. As of the previous 9 days, the stock’s Stochastic %D was 81.64%. Additionally, its Average True Range was 1.25.
During the past 100 days, NewAmsterdam Pharma Company NV’s (NAMS) raw stochastic average was set at 37.34%, which indicates a significant decrease from 69.34% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 40.38% in the past 14 days, which was lower than the 78.05% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $19.87, while its 200-day Moving Average is $19.87. Nevertheless, the first resistance level for the watch stands at $19.86 in the near term. At $20.73, the stock is likely to face the second major resistance level. The third major resistance level sits at $21.39. If the price goes on to break the first support level at $18.33, it is likely to go to the next support level at $17.67. Assuming the price breaks the second support level, the third support level stands at $16.80.
NewAmsterdam Pharma Company NV (NASDAQ: NAMS) Key Stats
There are 109,818K outstanding shares of the company, which has a market capitalization of 2.13 billion. As of now, sales total 45,560 K while income totals -241,600 K. Its latest quarter income was 12,770 K while its last quarter net income were -92,180 K.
